Company: WHWK
Filing Date: 2025-01-21
Form Type: PREM14A
Source: 0001193125-25-009599
Chunk: 17

Company: Whitehawk Therapeutics, Inc.
Filing Date: 2025-01-21
Form: PREM14A
Chunk 17
---
 page [●] of this proxy statement.

Why is Aadi in-licensingthe ADC Programs?

Aadi believes that entry into the License Agreement provides an opportunity to
strengthen its pipeline of development assets and, together with the PIPE Financing, strengthen its capital resources, positioning it to become a leading precision oncology company focused on developing novel treatments utilizing the next wave of
antibody-drug conjugate (ADC) therapies. Following the Divestiture, Aadi plans to focus primarily on advancing the ADC Programs designed for a broad range of cancerous diseases, including treatment of solid tumors, including non-small cell lung cancer (NSCLC), ovarian cancer, small cell lung cancer and neuroendocrine tumors. For a discussion of Aadi’s reasons for the PIPE Financing and the License Agreement, please see the sections
titled “The PIPE Financing and License Agreement—Reasons for the PIPE Financing and License Agreementand Recommendation of the Aadi Board of Directors” beginning on page [●] and “The ADC Programs”beginning on page [●] of this proxy statement.

What is the Registration Rights Agreement?

At the closing of the PIPE Financing, in connection with the Subscription Agreement, it is a condition to closing for Aadi to enter into a Registration Rights
Agreement (the “Registration Rights Agreement”) with the PIPE Investors. Pursuant to the Registration Rights Agreement, Aadi will prepare and file a resale registration statement with the SEC on or prior to the later of (i) thirty
(30) days following the closing of the PIPE Financing and (ii) five (5) business days following the filing of Aadi’s audited financial statements for the year ended December 31, 2024. Aadi will use its commercially reasonable efforts
to cause this registration statement to be declared effective by the SEC within 60 calendar days of the closing of the PIPE Financing (or within 90 calendar days if the SEC reviews the registration statement), subject to acceleration under certain
circumstances.

For more detail on the Registration Rights Agreement, see the section titled and“The PIPE Financing and License Agreement—PIPE Financing and Subscription Agreement—Registration Rights Agreement” beginning on page [●] of this proxy statement.

- 9 -

What will happen if stockholders do not approve the PIPE Financing at the Special Meeting? If, for any reason, the PIPE Financingis not consummated, Aadi will not complete the issuance of common stock and Pre-Funded Warrants pursuant to the Subscription Agreement and Aadi’s board of